Impact of Standardized Allergen-Removed Rhus verniciflua Stokes Extract on Advanced Adenocarcinoma of the Ampulla of Vater: A Case Series

Table 2

Patient response to aRVS extract treatment.

Patient number	Initial day of aRVS treatment*	Time from advanced stage diagnosis to aRVS treatment (month)	aRVS treatment duration (month)	Best response; RECIST	Progression-free survival (month)	Overall survival (month)
1	2007-02-28	7.6	6.0	PD	2.7	6.7
2	2007-06-01	17.3	4.6	PD	1.6	15.1
3	2007-06-18	10.5	4.7	SD	4.1	25.1
4	2009-09-09	8.9	15.5	PD	1.9	16.9
5	2010-07-14	35.3	5.1	PD	3.3	14.2
6	2010-07-23	3.8	20.0	SD	11.2	20.0 (alive)
7	2010-07-27	7.9	3.5	PD	1.7	10.3
8	2010-08-11	4.9	13.8	CR	11.3 (+)	19.4 (alive)
9	2011-01-14	0.5	2.4	PD	2.7	4.9
10	2011-01-26	11.8	4.0	PD	2.2	11.8
11	2011-03-16	1.2	10.7	CR	11.4 (+)	12.2 (alive)
12	2011-03-30	17.7	2.6	PD	3.3	6.7

∗The standardized allergen-removed Rhus verniciflua Stokes (aRVS) extract (1350 mg) was orally administered daily.
CR: complete response, PD: progressive disease, PR: partial response, and SD: stable disease.